DOPTELET Drug Insight

“DOPTELET Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about DOPTELET for thrombocytopenia and immune thrombocytopenic purpura (ITP) in the seven major markets. A detailed picture of the DOPTELET in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the DOPTELET. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DOPTELET market forecast analysis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies.

Drug Summary

DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to previous treatment.

For thrombocytopenia with chronic ITP, it is approved in the US. In the EU, Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for primary chronic ITP in adult patients who are refractory to other treatments.

It is approved in the US and EU for the treatment of thrombocytopenia with CLD. For thrombocytopenia with chronic ITP, it is approved in the US, and in the EU, Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for primary chronic ITP in adult patients who are refractory to other treatments.

It is being evaluated in pediatric subjects with immune thrombocytopenia (ITP) and thrombocytopenia after donor hematopoietic stem cell transplant. The Phase III trial for chemotherapy-induced thrombocytopenia did not meet the composite primary endpoint of avoiding platelet transfusions, chemotherapy dose reductions by 15% or greater, and chemotherapy dose delays by 4 days or more, according to the top-line result.

Dosage

Chronic ITP: Initiate DOPTELET at 20 mg (one tablet) once daily. Adjust the dose or frequency of dosing to maintain a platelet count greater than or equal to 50 × 109/L. Do not exceed 40 mg per day.

Mechanism of action

Avatrombopag is an orally bioavailable, small-molecule TPO receptor agonist that stimulates the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the DOPTELET description, mechanism of action, dosage and administration, research and development activities in thrombocytopenia and immune thrombocytopenic purpura (ITP).
• Elaborated details on DOPTELET regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DOPTELET research and development activities in thrombocytopenia and immune thrombocytopenic purpura (ITP) across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DOPTELET.
• The report contains forecasted sales of DOPTELET for thrombocytopenia and immune thrombocytopenic purpura (ITP) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for thrombocytopenia and immune thrombocytopenic purpura (ITP).
• The report also features the SWOT analysis with analyst views for DOPTELET in thrombocytopenia and immune thrombocytopenic purpura (ITP).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DOPTELET Analytical Perspective by DelveInsight

• In-depth DOPTELET Market Assessment

This report provides a detailed market assessment of DOPTELET for thrombocytopenia and immune thrombocytopenic purpura (ITP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• DOPTELET Clinical Assessment

The report provides the clinical trials information of DOPTELET for thrombocytopenia and immune thrombocytopenic purpura (ITP) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for thrombocytopenia and immune thrombocytopenic purpura (ITP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DOPTELET dominance.
• Other emerging products for thrombocytopenia and immune thrombocytopenic purpura (ITP) are expected to give tough market competition to DOPTELET and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DOPTELET in thrombocytopenia and immune thrombocytopenic purpura (ITP).
• Our in-depth analysis of the forecasted sales data of DOPTELET from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DOPTELET in thrombocytopenia and immune thrombocytopenic purpura (ITP).

Key Questions

• What is the product type, route of administration and mechanism of action of DOPTELET?
• What is the clinical trial status of the study related to DOPTELET in thrombocytopenia and immune thrombocytopenic purpura (ITP) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DOPTELET development?
• What are the key designations that have been granted to DOPTELET for thrombocytopenia and immune thrombocytopenic purpura (ITP)?
• What is the forecasted market scenario of DOPTELET for thrombocytopenia and immune thrombocytopenic purpura (ITP)?
• What are the forecasted sales of DOPTELET in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to DOPTELET for thrombocytopenia and immune thrombocytopenic purpura (ITP)?
• Which are the late-stage emerging therapies under development for the treatment of thrombocytopenia and immune thrombocytopenic purpura (ITP)?